These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33781017)

  • 1. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
    Pisano C; Tucci M; DI Stefano RF; Turco F; Samuelly A; Bungaro M; Vignani F; Tarenghi F; Scagliotti GV; DI Maio M; Buttigliero C
    Minerva Urol Nephrol; 2021 Dec; 73(6):803-814. PubMed ID: 33781017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
    Guan Y; Xiong H; Feng Y; Liao G; Tong T; Pang J
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):220-231. PubMed ID: 32034294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
    de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
    ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
    Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
    Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
    Kawahara T; Kato M; Tabata K; Kojima I; Yamada H; Kamihira O; Tsumura H; Iwamura M; Uemura H; Miyoshi Y
    BMC Cancer; 2020 Sep; 20(1):919. PubMed ID: 32977754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Goktas Aydin S; Kutlu Y; Muglu H; Aydin A; Acikgoz O; Hamdard J; Karci E; Bilici A; Olmez OF; Yildiz O
    Cancer Chemother Pharmacol; 2024 Jan; 93(1):71-78. PubMed ID: 37773537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
    Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
    Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
    Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
    Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
    Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone.
    Nieblas-Toscano D; Arenas-Bonilla AJ; Flores-Martín JF; Gutiérrez-Tejero F; Velarde-Muñoz C; Ramos-Alaminos CI; Salas-Moreno MC; Galisteo-Moya R; Moreno-Jiménez J
    Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):164-171. PubMed ID: 32035807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
    BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Di Stefano RF; Tucci M; Turco F; Samuelly A; Bungaro M; Pisano C; Vignani F; Gallicchio M; Scagliotti GV; Di Maio M; Buttigliero C
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):812-825. PubMed ID: 33603237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.
    Machidori A; Shiota M; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Eto M
    Urol Oncol; 2021 Jun; 39(6):365.e1-365.e7. PubMed ID: 33077351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.
    Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U
    PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
    Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
    Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
    Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
    Sciarra A; Gentilucci A; Cattarino S; Salsiccia S; Mariotti G
    Minerva Urol Nephrol; 2021 Dec; 73(6):863-865. PubMed ID: 35144373
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Küçükarda A; Gökyer A; Gökmen I; Özcan E; Hacıoğlu MB; Erdoğan B; Uzunoğlu S; Çiçin I
    Actas Urol Esp (Engl Ed); 2022 Jun; 46(5):301-309. PubMed ID: 35256324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
    Onal C; Sedef AM; Kose F; Oymak E; Guler OC; Sumbul AT; Aksoy S; Akkus Yildirim B; Besen AA; Muallaoglu S; Mertsoylu H; Ozyigit G
    Future Oncol; 2019 May; 15(13):1469-1479. PubMed ID: 30977383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.